Healiva buys critical cell therapy manufacturing assets from B. Braun

Healiva announced today that it acquired critical manufacturing assets from B. Braun’s B. Braun Medical AG Switzerland affiliate.

The companies declined to disclose financial details for the acquisition.

Lugano, Switzerland-based Healiva develops precision medicine for patients with chronic and acute wounds. It acquired a qualified cell bank for the manufacturing of its first cell therapy product.

The company said in a news release that the cell bank is “essential” for the GMP-compliant manufacturing of EpiDex. It designed EpiDex as an autologous epidermis derived from the patients own hair cells.

“This transaction will enable Healiva to accelerate the launch of EpiDex, which is projected for Q4 2023,” said Priyanka Dutta-Passecker, co-founder and CEO of Healiva. “This will allow us to deliver our clinically proven, surgery-free solution to patients with severe chronic wounds more promptly, shortening the path to market for EpiDe…

Read more
  • 0